Tag: MedinCell
MedinCell: half-yearly accounts include the first commercial revenues
(Boursier.com) — The 2023-2024 half-year accounts of MedinCell show revenues of 8.2 ME (+6.1% compared to the first half of the previous year) including 7 ME in turnover. This revenue…
Medincell: Net loss reduced in the first half
Read also (CercleFinance.com) – MedinCell set itself the objective on Wednesday of achieving operational profitability ‘as soon as possible’ and generating additional revenues through new partnerships with a view to…
MedinCell: 26.8 million euros in cash, visibility over twelve months – 12/19/2023 at 6:15 p.m.
(AOF) – As of September 30, 2023, MedinCell had cash and cash equivalents of 26.8 million euros including 15.0 million euros of non-risky current financial assets, compared to 6.5 million…
MedinCell: an analyst persists and signs
By Hector Chaunu Published on 12/20/2023 at 9:11 a.m. The 2023-2024 half-year accounts of MedinCell showed revenues of 8.2 ME (+6.1% compared to the…
MedinCell will participate in the Jefferies Global Healthcare conference – London, from November 14 to 16 – 11/06/2023 at 6:00 p.m.
• Christophe Douat, Chairman of the Management Board, and Richard Malamut, Medical Director, will present the portfolio of commercial and advanced clinical development products as part of the Global Healthcare…
MedinCell – Successful recruitment for the phase 3 clinical study of F14 (mdc-CWM), a first-in-class localized treatment to relieve pain after knee replacement surgery – 08/30/2023 at 18 :54
MedinCell Announces Successful Recruitment for Phase 3 Clinical Study of F14 (mdc-CWM), a First-in-Class Localized Treatment for Post-Knee Replacement Pain Relief – Recruitment is complete after randomization of 151 patients…
MedinCell: first positive feedback from Teva in the USA
(CercleFinance.com) – MedinCell stock rose on the Paris Stock Exchange on Thursday following the announcement by its partner Teva of the successful launch in the United States of a treatment…
MedinCell Partner Teva Announces Successful Launch of UZEDY™ – 2023-08-02 22:52
MedinCell Partner Teva Announces Successful Launch of UZEDY™ Euronext: MEDCL – Montpellier – France – August 2, 2023 – 10:00 p.m. ________________________________________________________________________________ Richard Francis, Chairman and Chief Executive Officer of…
MedinCell has received the last €10 million installment of the EIB loan
(AOF) – The drawing of this last tranche of a total loan of 40 million euros signed with the EIB in November 2022 was conditional on the approval by the…
MedinCell: receives the last installment of the EIB loan
(CercleFinance.com) – MedinCell announced this evening that it had received the last €10 million installment of the loan from the European Investment Bank (EIB). The drawing of this last tranche…
MedinCell will publish its annual results on June 26, 2023 (April 2022 – March 2023) – 06/05/2023 at 19:03
MedinCell will publish its annual results on June 26, 2023 (April 2022 – March 2023) Due to operational imperatives, the publication of the annual results for the fiscal year ended…
MedinCell: favorable characteristics of data from a phase 1 study of mdc-TJK – 05/22/2023 at 08:19
(AOF) – MedinCell announces that data from the Phase 1 study conducted by its partner Teva Pharmaceuticals of mdc-TJK, an investigational long-acting subcutaneous formulation of olanzapine for patients with schizophrenia,…